Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling
Kaixin Ding, Zhipeng Zhang, Zhengbin Han, Lei Shi, Xinzhi Li, Yutong Liu, Zhenzhi Li, Chongchong Zhao, Yifeng Cui, Liying Zhou, Bolin Xu, Wenjing Zhou, Yikui Zhao, Zhiqiang Wang, He Huang, Liwei Xie, Xiaowei Chen, Zheng Chen
Abstract
Maintaining glucose and lipid homeostasis is crucial for health, with dysregulation leading to metabolic diseases such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction–associated fatty liver disease (MAFLD). This study identifies alkylation repair homolog protein 5 (ALKBH5), an RNA N 6 -methyladenosine (m 6 A) demethylase, as a major regulator in metabolic disease. ALKBH5 is up-regulated in the liver during obesity and also phosphorylated by protein kinase A, causing its translocation to the cytosol. Hepatocyte-specific deletion of Alkbh5 reduces glucose and lipids by inhibiting the glucagon receptor (GCGR) and mammalian target of rapamycin complex 1 (mTORC1) signaling pathways. Targeted knockdown of hepatic Alkbh5 reverses T2DM and MAFLD in diabetic mice, highlighting its therapeutic potential. This study unveils a regulatory mechanism wherein ALKBH5 orchestrates glucose and lipid homeostasis by integrating the GCGR and mTORC1 pathways, providing insight into the regulation of metabolic diseases.